Top Tech Companies (144)
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Biocentis is an Imperial College London spin-out on a mission to develop eco-friendly genetic solutions to effectively and safely control the dangerous insect species that spread disease to humans, reduce biodiversity, or threaten food security. We leverage CRISPR to develop self-limiting gene drive technologies that are biological, environmentally friendly, and can be tailored to obtain levels of control that are...
Modern Synthesis is a London based biomaterial company connecting the dots between biology, material science and design to craft the next generation of biomaterials for the fashion industry
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using...
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics...
Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients...
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently...
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around...
The UK's leading provider of insect farms and insect technology • Our mission is to accelerate a global transition to sustainable protein, using insects and technology
Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.
Cytiva, now with the life sciences business from Pall Corporation, is a global life sciences leader dedicated to helping customers discover and commercialize the next generation of therapeutics. Together, we bring dedicated technical expertise and a broad portfolio of tools and technologies that enable the development, manufacture, and delivery of transformative medicines to patients. Visit cytiva.com to learn more.
LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology and robotics.
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success...
Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this...
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant...
At AviadoBio our mission is to potentially transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively...
